CDER's Janet Woodcock: Pharma, regulators have lessons to learn from Covid-19
When pharmaceutical companies, health care leaders and regulators finally get a chance to debrief and pull lessons learned from the coronavirus pandemic, a chief takeaway may revolve around the many missed research opportunities. However, learnings from Covid-19 may one day lead to novel trial design and increased cooperation among these players promise a better path forward when speed and safety need equal consideration. This message was among many shared by a leading regulator in a 9 November audio interview with editors at the New England Journal of Medicine (NEJM).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.